- The consumables segment is anticipated to dominate the market, this dominance is attributed to the increasing demand for customized drugs, which necessitate specialized consumables for pharmacogenetic testing
- This preference is due to its comprehensive ability to analyze genetic variations that influence drug response, providing valuable insights for personalized treatment plans
- Variations in this gene significantly affect the metabolism of several antidepressants, making it a critical target for pharmacogenetic testing in depression treatment
- Hospitals and clinics are anticipated to be the leading end-users. Their significant share is driven by the increasing integration of pharmacogenetic testing into clinical practice to enhance treatment outcomes for patients with psychiatric disorders
- For instance, a study conducted in British Columbia, Canada, demonstrated that pharmacogenomic testing for antidepressants could reduce the time and cost associated with finding the most effective medication for patients.
